Hepatitis
Conference Coverage
High SVR achieved in decompensated HCV patients with 12-week therapy
The findings are encouraging because current treatment options for patients with HCV who have decompensated liver disease are limited, Dr....
Conference Coverage
New direct-acting antivirals for HCV perform well in real world
Discontinuation rates for the new direct-acting antivirals are “not a major issue” in real world clinical practice.
Conference Coverage
VIDEO: Ledipasvir/sofosbuvir highly effective in treatment-naive HCV GT1
Combination treatment with ledipasvir/sofosbuvir is highly effective for treatment-naive hepatitis C virus genotype 1 patients in routine medical...
Conference Coverage
Eight-week, three-drug regimen produces SVR over 90% in HCV
A triple antiviral combination with direct-acting antiviral agents was associated with high rates of sustained virologic response across all three...
News
Sofosbuvir plus velpatasvir effective at treating HCV genotype 1 and 3 patients
Patients with genotype 1 or 3 hepatitis C virus infection responded well to therapy with 400 mg of sofosbuvir combined with 100 mg of velpatasvir...
News
Sofosbuvir-velpatasvir combo effective in treatment-naive HCV patients*
A combination of sofosbuvir and velpatasvir effectively treated all six hepatitis C virus genotypes in treatment-naive patients without cirrhosis...
News
FDA warns of serious liver injury from HCV drugs Viekira Pak and Technivie
The Food and Drug Administration has issued a safety alert warning of possible serious liver injury as a result of the hepatitis C drugs Viekira...
Conference Coverage
IDWeek: Despite better drugs, HCV deaths keep rising
Despite better therapies, deaths from hepatitis C virus infection continue to rise, indicating poor penetrance of medications and care to patients...
News
High ALT/AST ratio linked to fatty liver risk in HCV
Individuals infected with the hepatitis C virus who have a higher ratio of alanine aminotransferase to aspartate aminotransferase may be at...
News
Sofosbuvir reduces liver fibrosis in chronic hepatitis C
Key clinical point: Treatment with sofosbuvir achieved clinically significant fibrosis regression and potential reduction of cirrhosis-associated...
News
Hepatitis C drove steep rises in cirrhosis, HCC, and related deaths
Cirrhosis nearly doubled among Veterans Affairs patients between 2001 and 2013, while cirrhosis-related mortality rose by about 50% and deaths...